Essity in the news

Essity B stock modestly rose on September 10, 2026, supported by its Q2 2026 financial performance.

L'Oreal, RB, and Essity launched a "Shop Responsibly" campaign to encourage considerate shopping habits during the COVID-19 pandemic.

Essity repurchased 273,715 of its own Class B shares as part of a SEK 3bn buyback program, financed by operational cash flow.

A court ruling has limited the scope of questioning company employees during evidence preservation in a patent dispute between Essity and WEPA concerning hygiene paper.

Essity B stock experienced price movement due to UBS downgrading its rating and the company's ongoing share buyback program, while facing higher operational costs.

Essity B stock remains stable, supported by its resilient hygiene and health product business, improved profitability, and debt reduction efforts.

UBS downgraded Essity to 'Sell' due to rising raw material costs and lower growth expectations.

Essity is conducting a global creative review after expanding its healthcare business through major femcare brand acquisitions in North America and Brazil.

Essity is acquiring Kenvue's Brazilian feminine care business for US$284 million.

Essity received unconditional approval from Brazil's competition authority to acquire Kenvue's feminine-care business, including Carefree, Sempre Livre, and o.b. brands.

Essity's stock dropped after UBS downgraded it to a Sell rating, citing softening fundamentals and existing margin concerns.

UBS downgraded Essity's stock rating to 'sell' and lowered its price target to SEK 235.

UBS downgraded Essity's stock to sell with a reduced price target due to concerns about growth, margins, and potential divestment, causing the stock to fall.

Essity's shares dropped after UBS downgraded its rating to 'sell' due to concerns about sales growth, raw material costs, and consumer paper product uncertainty.

UBS has downgraded Essity to sell, citing weak growth, margin pressure, and uncertainty in Consumer Tissue.

Essity approved a 2.85 million investment in hydrogen-ready technology for its North Wales mill.

Essity is investing 2.85 million in hydrogen-ready technology at its North Wales mill to cut emissions and improve efficiency.

Essity's B stock is stable, supported by strong demand for hygiene products and improved profitability due to cost management and pricing strategies.

Citadel Advisors has rejoined other public short-sellers in Essity, with 3.95% of the company's capital currently being shorted.

A recent quiz revealed insights into stock market trends, popular stock purchases, Essity's acquisition in Brazil, the US national debt, and a new financial education app for children.